---
title: "Canadian cannabis firm Organigram's Q1 net revenue jumps 49%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275445671.md"
datetime: "2026-02-10T11:08:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275445671.md)
  - [en](https://longbridge.com/en/news/275445671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275445671.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275445671.md) | [繁體中文](https://longbridge.com/zh-HK/news/275445671.md)


# Canadian cannabis firm Organigram's Q1 net revenue jumps 49%

)

Overview

-   Canada cannabis firm’s fiscal Q1 net revenue rose 49% yr/yr but missed analyst expectations
-   Adjusted EBITDA for fiscal Q1 increased significantly, driven by higher recreational and international revenue
-   Company achieved genetic screening breakthrough for powdery mildew resistance, improving yield stability

Outlook

-   Organigram expects continued growth in international sales throughout Fiscal 2026
-   Company is preparing for EU-GMP certification for its Moncton facility

Result Drivers

-   MOTIF ACQUISITION - Net revenue growth driven by contributions from Motif Labs acquisition and increased international sales
-   GROSS MARGIN IMPROVEMENT - Adjusted gross margin rose due to operational efficiencies, higher flower yields, and Motif integration synergies
-   GENETIC BREAKTHROUGH - Achieved genetic screening breakthrough for powdery mildew resistance, enhancing yield stability and reducing costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss C$63.54 C$73.15

Revenue mln mln (5

Analysts

)

Q1 Gross C$97.30

Revenue mln

Q1 Net C$19.97

Income mln

### Q1 C$5.27

Adjusted mln

### EBITDA

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 4 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the healthcare facilities & services peer group is “buy”
-   Wall Street’s median 12-month price target for Organigram Global Inc is C$3.25, about 49.8% above its February 9 closing price of C$2.17

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### 相关股票

- [Organigram (OGI.US)](https://longbridge.com/zh-CN/quote/OGI.US.md)

## 相关资讯与研究

- [Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting | OGI Stock News](https://longbridge.com/zh-CN/news/278536189.md)
- [OrganiGram Global Inc. steigert im ersten Quartal das bereinigte EBITDA auf 5,27 Mio. CAD, ein Plus um das 3,7-Fache](https://longbridge.com/zh-CN/news/275444292.md)
- [Earnings Preview For OrganiGram Holdings](https://longbridge.com/zh-CN/news/275357374.md)
- [OrganiGram Global Inc. Releases MD&A for Three Months Ended December 31, 2025](https://longbridge.com/zh-CN/news/275459685.md)
- [OrganiGram Global Inc. veröffentlicht MD&A-Bericht für das erste Quartal 2026](https://longbridge.com/zh-CN/news/275459714.md)